Application Notes
Optibumin® X, a Defined Recombinant Human Serum Albumin, Enhances iPSC Expansion While Maintaining Pluripotency
PDF · Published 2026-11-14 · 3 min read
Application Note
Albumin earns its place in robust hPSC media by doing several jobs at once: it stabilizes FGF2 at 37 °C, prevents insulin loss in low-protein media, supplies a large share of extracellular antioxidant capacity through its free Cys34, carries poorly soluble nutrients, buffers shear and mops up metabolic byproducts. Defined media such as Essential 8 left it out anyway — not because albumin stopped being useful, but because plasma-derived albumin could not be made consistent. Only one of five commercial BSA batches supported long-term self-renewal in the work that produced E8, so the field accepted a loss of robustness to escape the variability.
Optibumin® X is InVitria’s cGMP, recombinant, animal-origin-free human serum albumin: lipid-stripped, a single dominant isoform, and consistent from lot to lot. This application note asks whether adding it back to a defined medium restores albumin’s benefits without reintroducing the variability that caused its removal.
What was tested
Human iPSCs were seeded at 20,000 cells/well on vitronectin-coated plates and serially passaged five times on a weekend-free feeding schedule in E8 Flex alone, or E8 Flex supplemented with 5 mg/mL Optibumin® X or clinical-grade plasma-derived HSA (pHSA) — three lots of each albumin, three replicate wells per lot. mTeSR™ Plus was included as a general performance benchmark. Plates were imaged every 4 h on an Incucyte® SX5 and confluence quantified to derive fold expansion and population doublings. At the end of passage 5, cells were analyzed by intracellular flow cytometry for Oct4, Sox2 and Nanog with a Zombie Aqua™ viability stain. Total fatty acid was measured by GC-FID of fatty acid methyl esters across three Optibumin® X lots and four pHSA lots.
Key results
- Expansion: 18.9 versus 13.0 cumulative population doublings over five passages in E8 Flex with versus without Optibumin® X (p < 0.05), approaching the mTeSR Plus benchmark. Over the first 96 h, mean fold expansion was 4.1 versus 2.6.
- Yield: ~1.5-fold more cells per harvest than E8 Flex alone (~3.1×105 versus ~2.0×105 cells per well at passage 5).
- Pluripotency and viability held: all three Optibumin® X lots remained >97% Oct4/Sox2/Nanog triple-positive with >94% viability, with no significant differences between lots. Viability was modestly but significantly higher than E8 Flex alone for every lot (94.7–96.3% versus 93.8%; p < 0.01).
- Morphology unchanged: after five passages, colonies in all three lots kept the compact, tightly packed morphology and defined borders of undifferentiated iPSCs, with no visible regions of spontaneous differentiation.
- Plasma-derived HSA was not reliable: pHSA reached 17.4 doublings, which did not differ significantly from E8 Flex because of high lot-to-lot variance. One of three lots significantly reduced both pluripotency and viability — the lot-dependent cell quality that led to albumin’s removal from E8 in the first place.
- ~35× less fatty acid: Optibumin® X carried 70 µg/mL total fatty acid versus 2,494 µg/mL for clinical-grade pHSA (~97% less), and the pHSA lots varied widely from one another.
Why the lipid load matters
Albumin’s principal physiological role is fatty acid transport — it carries ~99% of plasma non-esterified fatty acids across seven binding sites. In iPSC culture that cargo is not a neutral background: albumin-bound fatty acids are biologically active in hPSCs, and fatty acid loading changes albumin’s conformation and how it binds other medium components. E8 was deliberately finalized as a lipid-free medium, so an albumin arriving with an uncontrolled lipid load reintroduces exactly the variable the medium was designed to exclude. Because Optibumin® X is lipid-stripped, its effect reflects the protein’s own functions rather than lipid delivery — and where lipids are wanted, they can be loaded onto it at known concentrations as a deliberate choice rather than an inherited one.
Structural consistency behind the performance
Orthogonal characterization supports the functional result: Optibumin® X shows 0.47% total aggregates versus 7.52% for pHSA, 99% reduced Cys34 versus ~60%, and a single main charge isoform with no acidic or basic variants detected, against 3–4 peaks in pHSA with the acidic fraction reaching 53%. The differences hold for both means and variances.
Conclusion
Albumin was left out of defined iPSC media because plasma-derived albumin could not be made consistent. Added to E8 Flex at 5 mg/mL, Optibumin® X increased expansion over five passages and maintained normal colony morphology, >97% Oct4/Sox2/Nanog triple-positive cells and >94% viability, consistently across three lots — adding albumin’s functions to a defined medium without adding an undefined input.
Authors
Andy Su, MSc; Mark Stathos, PhD; Wren Michaels, PhD; and Jacob Weber, PhD. InVitria, Inc., USA.
The following content is gated. Please, subscribe to open access to it.
More resources
Keep reading.
Functional Characterization of Lacromin® Recombinant Human Holo-Lactoferrin for Cell Culture and Advanced Therapy Applications
Recombinant Albumin Reduces Lentiviral Vector Titer Loss During 24-Hour Hold Times
Talk to a Scientist
See how rHSA performs in your media.
Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.